TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/23/2019 |
| Start Date: | March 2019 |
| End Date: | March 2022 |
| Contact: | Tizona Therapeutics, Inc. |
| Email: | clinicaltrials@tizonatx.com |
| Phone: | 888-585-2990 |
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity,
leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of
immunosuppressive adenosine, which may change the tumor microenvironment and promote
anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of
TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and
standard chemotherapies.
leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of
immunosuppressive adenosine, which may change the tumor microenvironment and promote
anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of
TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and
standard chemotherapies.
Abreviated Inclusion Criteria
1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or
- eligible to receive single-agent pembrolizumab as standard of care, or
- eligible to receive single-agent docetaxel as standard of care, or
- advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus
nab-paclitaxel as standard of care.
2. Age 18 years or older, is willing and able to provide informed consent
3. Evidence of measurable disease
4. Life expectancy > 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance
status of 0-1
Abbreviated Exclusion Criteria
1. History of allergy or hypersensitivity to study treatment components. Patients with a
history of severe hypersensitivity reaction to any monoclonal antibody.
2. Use of investigational agent within 28 days prior to the first dose of study treatment
and throughout the study
3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive
therapy
4. History of severe autoimmune disease
5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing
treatment
We found this trial at
1
site
Click here to add this to my saved trials
